• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

CooperSurgical® Acquires AEGEA Medical

Share:

February 10, 2021

CooperSurgical announced today the acquisition of California-based, AEGEA Medical and its FDA-approved Mara™ Water Vapor Ablation System. The acquisition builds on over 30 years of experience in women’s healthcare and complements CooperSurgical’s growing portfolio of medical products focused on clinic and practice-based women’s health.

Mara is an endometrial ablation treatment that uses water vapor to safely treat heavy menstrual bleeding, specifically designed for use in the doctor’s office. Mara is a two-minute, in-office treatment that ablates the lining of the uterus, the source of heavy menstrual bleeding in women who have not reached menopause. Heavy menstrual bleeding, also known as menorrhagia, is a common condition about one-third of women seek treatment for during their lifetimes1.

Clinical study data demonstrates that Mara safely and effectively reduces heavy menstrual bleeding and improves a woman’s quality of life. Mara treats patients with myomas, large cavities and also provides post-ablation cavity access.

“I’d like to thank Maria Sainz and her team, CEO of AEGEA, for her dedication to innovation in women’s health,” said Holly Sheffield, President of CooperSurgical. “The Mara Water Vapor Ablation System gives women a great option for a safe and convenient in-office procedure to help with what can often be a debilitating health issue.”

Mara Clinical Results

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

One year after treatment in an international, multi-center pivotal clinical trial that enrolled 155 women, 93% of women reported no to moderate bleeding2. Results also demonstrated the following:

  • 99% of patients experienced improvement in quality of life3
  • 91% of patients satisfied or very satisfied with procedure2,3
  • 93% said they would recommend it to a friend2

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Actu-Real Inc. and Jehangir Clinical Dev Centre Announce Strategic Collaboration to Further Real-World ResearchActu-Real Inc. and Jehangir Clinical Dev Centre Announce Strategic Collaboration to Further Real-World Research
  • ImaginAB Announces Extension of Long-Standing Partnership with Boehringer IngelheimImaginAB Announces Extension of Long-Standing Partnership with Boehringer Ingelheim
  • Amplifybio Acquires Pact Pharma Assets to Enhance Cell and Gene Therapy Characterization CapabilitiesAmplifybio Acquires Pact Pharma Assets to Enhance Cell and Gene Therapy Characterization Capabilities
  • Pointclickcare Acquires American Healthtech, Expands Senior Care ReachPointclickcare Acquires American Healthtech, Expands Senior Care Reach
  • Brainlab Acquires Medical Video Game Innovator Level ExBrainlab Acquires Medical Video Game Innovator Level Ex
  • Kraig Biocraft Laboratories takes possession of factory in VietnamKraig Biocraft Laboratories takes possession of factory in Vietnam
  • The Lipid Nanoparticles (LNPs) CDMO Market is Projected to Grow at a CAGR of 13.8%, During the Period 2022-2030, ClaimsThe Lipid Nanoparticles (LNPs) CDMO Market is Projected to Grow at a CAGR of 13.8%, During the Period 2022-2030, Claims
  • R1 Expands Revenue Cycle Management Offering to More Medical GroupsR1 Expands Revenue Cycle Management Offering to More Medical Groups

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications